Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P00156
UPID:
CYB_HUMAN
Alternative names:
Complex III subunit 3; Complex III subunit III; Cytochrome b-c1 complex subunit 3; Ubiquinol-cytochrome-c reductase complex cytochrome b subunit
Alternative UPACC:
P00156; Q34786; Q8HBR6; Q8HNQ0; Q8HNQ1; Q8HNQ9; Q8HNR4; Q8HNR7; Q8W7V8; Q8WCV9; Q8WCY2; Q8WCY7; Q8WCY8; Q9B1A6; Q9B1B6; Q9B1B8; Q9B1D4; Q9B1X6; Q9B2V0; Q9B2V8; Q9B2W0; Q9B2W3; Q9B2W8; Q9B2X1; Q9B2X7; Q9B2X9; Q9B2Y3; Q9B2Z0; Q9B2Z4; Q9T6H6; Q9T9Y0; Q9TEH4
Background:
Cytochrome b, known as Complex III subunit 3, plays a pivotal role in the mitochondrial respiratory chain. It facilitates electron transfer from ubiquinol to cytochrome c, contributing to ATP synthesis. This protein's alternative names include Complex III subunit III and Ubiquinol-cytochrome-c reductase complex cytochrome b subunit.
Therapeutic significance:
Cytochrome b's malfunction is linked to diseases such as Cardiomyopathy, infantile histiocytoid, and Leber hereditary optic neuropathy. These associations underscore the protein's potential as a target for therapeutic intervention in mitochondrial and cardiovascular disorders.